2006-12-04

Perceptronix's First ClearSign(TM) Lung Cancer Testing Facility


Vancouver, Canada (ots/PRNewswire) - Perceptronix Medical Inc.("Perceptronix") announced today that it has opened its first sputuminduction facility at MDS Metro Laboratory Services' Victoria DrivePatient Service Centre in Vancouver. This facility will be the firstcentre to offer sputum induction for Perceptronix's ClearSign(TM)Sputum Test ("ClearSign(TM)").

ClearSign(TM) is a simple, non-invasive, early detection test forlung cancer. The test recently received Health Canada approval and isthe first lung cancer test to be approved in North America.

ClearSign(TM) is performed on sputum - the material brought upfrom the lungs after a deep cough - collected using an inductionprocedure where coughing is induced by breathing salt water vapour.Sputum samples are analyzed by Perceptronix to yield a ClearSign(TM)score which indicates the likelihood that an individual has lungcancer, similar to other cancer detection tests such as the Pap testfor cervical cancer or the PSA test for prostate cancer.

"We are pleased to be able to provide a convenient location tofacilitate sputum collection and analysis, and expect this collectionsite to be the first of many across Canada that will offer thisservice," says Dr. Bojana Turic, Perceptronix's Vice-President andChief Operating Officer.

Lung cancer is a prevalent form of cancer in both men and womenand results in the greatest number of cancer related deathsworldwide. In 2002, 1.35 million people were diagnosed with lungcancer and approximately 1.2 million people, or 18% of the world'scancer deaths were as a result of lung cancer. Early detection ofcancer is key to a positive outcome. Patients diagnosed with stage Ilung cancer have a 70% five year survival rate, which issignificantly higher than the 10% survival rate among those diagnosedwith stage III lung cancer or worse. The ClearSign(TM) test offersphysicians a new tool to determine the likelihood their patientharbours lung cancer, even before obvious symptoms are evident.

About Perceptronix suite of technologies

Perceptronix's suite of technologies and laboratory services isdesigned to approach cancer diagnosis comprehensively through earlydetection, localization, diagnosis and follow-up. The first ofPerceptronix's technologies to receive regulatory approvals are:

- ClearSign(TM) Sputum Test - This test is used for early lung cancer detection. ClearSign(TM) has a Health Canada license and CE Mark; - ClearCyte(TM) Test - This test is used to measure "gross genomic aberrations" (DNA Ploidy) to assist physicians with clinical diagnosis and prognosis of cancer. ClearCyte(TM) has a Health Canada license and CE Mark;

The Perceptronix Clinical Quantitative Cytology Laboratory inVancouver, Canada currently performs the ClearSign(TM) Sputum Testand the ClearCyte(TM) Test. This laboratory operates under guidanceand accreditation from the Diagnostic Accreditation Program of theBritish Columbia College of Physicians and Surgeons.

About Perceptronix Medical Inc. (www.perceptronix.com)

Perceptronix is a private, cancer diagnostics company based inVancouver, Canada. Perceptronix commercializes early cancer detectiontechnologies developed in partnership with the BC Cancer Agency(www.bccancer.bc.ca), a world-leader in cancer care and research anda pioneer in early cancer detection programs.

This news release is not, and under no circumstances is to beconstrued as, an advertisement, solicitation or offering ofsecurities of Perceptronix Medical Inc. The statements made in thisnews release may contain certain forward-looking statements thatinvolve a number of risks and uncertainties. Actual events orresults may differ from the Company's expectations.

ots Originaltext: Perceptronix Medical Inc.Im Internet recherchierbar: http://www.presseportal.de

Contact:For further information: Lydia Taylor, Director, Business Development, Perceptronix Medical Inc., Phone: +1-604-629-8785, info@perceptronix.com; Media Contact: Don Bradley, James Hoggan & Associates Inc., Phone: +1-604-739-7500, Mobile: +1-604-961-3883, dbradley@hoggan.com

Perceptronix Medical Inc.

Zurück zur Übersiche Medizin-Nachrichten

Preisvergleich Medikamente
Medikament oder PZN:   
In Zusammenarbeit mit Medizinfuchs

News

Perceptronix's First ClearSign(TM) Lung Cancer Testing Facility

Medizin-News